OBR Daily Commentary - Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

forumImage

Supreme Court to Review Biosimilar Battle Between Amgen and Sandoz

(STAT Plus/Pharmalot) Apr 25, 2017 - A hotly anticipated hearing takes place at the US Supreme Court on Wednesday about biosimilars and the eventual decision is expected to have widespread implications for health care costs.

Howard S. Hochster, MD (Posted: April 26, 2017)

quotesFascinating legal wrangling as the Supremes parse the wording of the BPCIA (Biologic Price Competition and Innovation Act). At stake, whether the biosimilar manufacturer must supply the originator company with a copy of their BLA application, and whether an additional 180 day waiting period Is required following actual FDA approval of the biosimilar for the originator to issue patent litigation. This would invalidate notification prior to the formal licensure. Who knew biosimilars could be so exciting and reach SCOTUS ??quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Novartis's Next Challenge: Pricing Breakthrough Cancer Treatment

(Bloomberg) June 8, 2017 - Novartis AG, set to beat Kite Pharma Inc. to the finish line in one of the most promising new areas of cancer research, is examining how to price a revolutionary therapy patients will need to take just once.

admin (Posted: June 08, 2017)

quotesTestquotes

Read Article arrow
Add Comment 1 Comment
forumImage

At $475,000, New Cancer Drug Raises Thorny Questions About Drug Pricing — And Value

(STAT/The Pharmalot View) Sept 4, 2017 - A first-of-its-kind cancer treatment is generating unbridled excitement — but also underscoring intense concerns over pricing and value.

Thomas Marsland, MD (Posted: September 05, 2017)

quotesWOW...that is a hunk of change...BUT it would appear that Novartis is at least following some of the suggestions in the recent ASCO paper on drug prices. They would appear to be looking at whether the drug works or not as part of the pricing. In addition they are also considering different pricing for different diseases with different efficacy and hence a somewhat different value proposition. Both approaches suggested in the ASCO report. With that said, $475,000 is still a heck of a lot of money. There is still very much a lack of transparency in how they came up with that number. It is interesting the market was predicting even higher pricing so this number makes them look good. They quote a billion dollars in investment but that is the number quoted for any new drug so why the huge pricing difference for this drug compared to other new innovative cancer therapies. Clearly Novartis has taken some steps toward better drug pricing but no question we still need to do better at controlling new drug costs (some old ones too...) quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...